PharmAla engages Corealis for ALA-002 formulation and clinical GMP supply
Company / institutional announcement · PharmAla Biotech / GlobeNewswire
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What changed
PharmAla signed an agreement with Corealis Pharma for ALA-002 drug-product development and GMP clinical supply. Corealis has begun formulation work in Laval, Québec, with an initial 50 mg capsule planned. Manufacturing of the first GMP batch is conditional on completing development activities. The agreement establishes a development and supply arrangement, rather than a product approval.
Why it may matter
Analysis: The arrangement may provide a clearer path to reproducible clinical drug product, with formulation readiness remaining a prerequisite for manufacturing.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections